PARIS — In patients with hepatitis C virus genotype 4, 8 weeks of Zepatier showed effective treatment of the virus, according to a presentation at the International Liver Congress 2018.
“This is an ongoing study investigating a novel 8-week treatment regimen of elbasvir/grazoprevir in participants with genotype 4 infection,” Tarik Asselah, MD, University Paris Diderot, said in his presentation. “We have high rates of SVR among treatment-naive participants with mild to moderate fibrosis who have completed follow up.”
The study Asselah presented included patients with HCV genotype 4. The researchers randomly assigned treatment-naive participants with mild to moderate fibrosis to receive Zepatier (elbasvir/grazoprevir, Merck) for 8 weeks (n = 53) or 12 weeks (n = 64).